WO2004022593A3 - Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules - Google Patents

Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules Download PDF

Info

Publication number
WO2004022593A3
WO2004022593A3 PCT/IB2003/004347 IB0304347W WO2004022593A3 WO 2004022593 A3 WO2004022593 A3 WO 2004022593A3 IB 0304347 W IB0304347 W IB 0304347W WO 2004022593 A3 WO2004022593 A3 WO 2004022593A3
Authority
WO
WIPO (PCT)
Prior art keywords
cytokines
nucleic acid
acid molecules
encoding nucleic
higher stability
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2003/004347
Other languages
French (fr)
Other versions
WO2004022593A8 (en
WO2004022593A2 (en
Inventor
Rene Gantier
Thierry Guyon
Manuel Vega
Lila Drittanti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nautilus Biotech SA
Original Assignee
Nautilus Biotech SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nautilus Biotech SA filed Critical Nautilus Biotech SA
Priority to AU2003263552A priority Critical patent/AU2003263552A1/en
Priority to DE60332358T priority patent/DE60332358D1/en
Priority to CA002498319A priority patent/CA2498319A1/en
Priority to EP03794017A priority patent/EP1539960B1/en
Priority to AT03794017T priority patent/ATE466085T1/en
Publication of WO2004022593A2 publication Critical patent/WO2004022593A2/en
Publication of WO2004022593A3 publication Critical patent/WO2004022593A3/en
Anticipated expiration legal-status Critical
Publication of WO2004022593A8 publication Critical patent/WO2004022593A8/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)

Abstract

Processes and systems for the high throughput directed evolution of peptides and proteins, particularly cytokines that act in complex biological settings, are provided. Also provided is a rational method for generating protein variants and the resulting variants.
PCT/IB2003/004347 2002-09-09 2003-09-08 Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules Ceased WO2004022593A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2003263552A AU2003263552A1 (en) 2002-09-09 2003-09-08 Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
DE60332358T DE60332358D1 (en) 2002-09-09 2003-09-08 PROTEASE-RESISTANT MODIFIED INTERFERON ALPHA POLYPEPTIDE
CA002498319A CA2498319A1 (en) 2002-09-09 2003-09-08 Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
EP03794017A EP1539960B1 (en) 2002-09-09 2003-09-08 Protease-resistant modified interferon alpha polypeptides
AT03794017T ATE466085T1 (en) 2002-09-09 2003-09-08 PROTEASE-RESISTANT MODIFIED INTERFERON ALPHA POLYPEPTIDES

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US40989802P 2002-09-09 2002-09-09
US60/409,898 2002-09-09
US45713503P 2003-03-21 2003-03-21
US60/457,135 2003-03-21

Publications (3)

Publication Number Publication Date
WO2004022593A2 WO2004022593A2 (en) 2004-03-18
WO2004022593A3 true WO2004022593A3 (en) 2004-07-15
WO2004022593A8 WO2004022593A8 (en) 2007-05-18

Family

ID=31981642

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2003/004347 Ceased WO2004022593A2 (en) 2002-09-09 2003-09-08 Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules

Country Status (8)

Country Link
US (12) US7611700B2 (en)
EP (1) EP1539960B1 (en)
AT (1) ATE466085T1 (en)
AU (1) AU2003263552A1 (en)
CA (1) CA2498319A1 (en)
DE (1) DE60332358D1 (en)
ES (1) ES2343518T3 (en)
WO (1) WO2004022593A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11746137B2 (en) 2020-03-31 2023-09-05 Hanmi Pharm. Co., Ltd. Immunostimulating IL-2 analogs

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2808804B1 (en) * 2000-05-09 2002-08-02 Nautilus Biotech METHOD FOR DETERMINING THE TITLE OF BIOLOGICAL AGENTS IN REAL TIME IN LIVING TARGET CELLS AND ITS APPLICATIONS
US20030129203A1 (en) * 2001-08-27 2003-07-10 Nautilus Biotech S.A. Mutant recombinant adeno-associated viruses
US7647184B2 (en) 2001-08-27 2010-01-12 Hanall Pharmaceuticals, Co. Ltd High throughput directed evolution by rational mutagenesis
CA2491567A1 (en) * 2002-07-01 2004-01-08 The Kenneth S. Warren Institute, Inc. Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs
DE60332358D1 (en) * 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd PROTEASE-RESISTANT MODIFIED INTERFERON ALPHA POLYPEPTIDE
US20060020396A1 (en) * 2002-09-09 2006-01-26 Rene Gantier Rational directed protein evolution using two-dimensional rational mutagenesis scanning
US20050202438A1 (en) * 2002-09-09 2005-09-15 Rene Gantier Rational directed protein evolution using two-dimensional rational mutagenesis scanning
AU2003277088A1 (en) * 2002-10-01 2004-04-23 Xencor, Inc Interferon variants with improved properties
US20050054053A1 (en) * 2002-10-01 2005-03-10 Xencor, Inc. Interferon variants with improved properties
CA2501295A1 (en) * 2002-10-02 2004-04-15 Jack Nguyen Methods of generating and screening for proteases with altered specificity
WO2004074486A2 (en) * 2003-02-18 2004-09-02 Merck Patent Gmbh Fusion proteins of interferon alpha muteins with improved properties
WO2006076014A2 (en) * 2004-04-30 2006-07-20 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Interferon-alpha constructs for use in the treatment of sars
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
CA2576030A1 (en) * 2004-08-09 2006-02-23 Alios Biopharma Inc. Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same
US20060073563A1 (en) * 2004-09-02 2006-04-06 Xencor, Inc. Erythropoietin derivatives with altered immunogenicity
US7998930B2 (en) * 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
US7211973B1 (en) * 2005-01-07 2007-05-01 Marvell Asia Pte, Ltd. System and process for utilizing back electromotive force in disk drives
JP2008527980A (en) * 2005-01-25 2008-07-31 アポロ ライフ サイエンシズ リミテッド Molecule and its chimeric molecule
WO2006111745A2 (en) * 2005-04-20 2006-10-26 Viragen Incorporated Composition and method for treating viral infection
EP1877434A2 (en) * 2005-05-04 2008-01-16 Nautilus Biotech Modified interferon-gamma polypeptides and methods for using modified interferon-gamma polypeptides
KR20080037656A (en) * 2005-06-20 2008-04-30 펩젠 코포레이션 Low-toxic long-circulating human interferon-alpha analogs and chimeras of interferon tau
EP1909822B1 (en) * 2005-06-29 2013-09-25 Yeda Research And Development Co., Ltd. Recombinant interferon alpha 2 (ifn alpha 2) mutants
WO2007098548A1 (en) * 2006-03-01 2007-09-07 Apollo Life Sciences Limited A molecule and chimeric molecules thereof
WO2007098547A1 (en) * 2006-03-01 2007-09-07 Apollo Life Sciences Limited A molecule and chimeric molecules thereof
US20080038224A1 (en) * 2006-03-28 2008-02-14 Thierry Guyon Modified interferon-beta (IFN-beta) polypeptides
US20080096819A1 (en) 2006-05-02 2008-04-24 Allozyne, Inc. Amino acid substituted molecules
EP2444499A3 (en) 2006-05-02 2012-05-09 Allozyne, Inc. Amino acid substituted molecules
EP2423305A1 (en) 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modified coagulation factor IX polypeptides and use thereof for treatment
AR078117A1 (en) * 2006-06-20 2011-10-19 Protech Pharma S A A RECOMBINANT MUTEIN OF THE GLICOSILATED HUMAN ALPHA INTERFERON, A CODIFYING GENE FOR SUCH MUTEIN, A METHOD OF PRODUCTION OF SUCH GENE, A METHOD FOR OBTAINING A EUCARIOTE CELL MANUFACTURING THIS MUTEINE, A METHOD FOR A MUTE DIFFERENT PROCEDURE
FR2905375A1 (en) * 2006-08-29 2008-03-07 Biomethodes Sa Thermostable variants of human interferon alpha useful for preparing antiviral, antiproliferative or immunomodulatory medicaments have one or more selected amino acid substitutions
CA2664304C (en) 2006-09-28 2017-08-22 Schering Corporation Use of pegylated il-10 to treat cancer
AR063239A1 (en) 2006-10-10 2009-01-14 Univ Australian PROCEDURE FOR THE GENERATION OF PROTEIN AND USES OF THE SAME
CN101678079B (en) 2006-11-28 2013-12-25 韩诺生物制约株式会社 Modified erythropoietin polypeptides and uses thereof for treatment
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
US7625555B2 (en) * 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins
CA2707840A1 (en) * 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
US20120264686A9 (en) 2008-05-29 2012-10-18 Hanall Biopharma Co. Ltd Modified erythropoietin (epo) polypeptides that exhibit increased protease resistance and pharmaceutical compositions thereof
KR20110039348A (en) 2008-08-06 2011-04-15 노보 노르디스크 헬스 케어 악티엔게젤샤프트 Conjugated Proteins with Extended In Vivo Efficacy
EP3348281B1 (en) 2008-12-17 2023-07-05 Merck Sharp & Dohme Corp. Mono- and di-peg il-10 production; and uses
WO2010085086A2 (en) * 2009-01-20 2010-07-29 한올바이오파마 주식회사 Modified human thrombopoietin polypeptide fragment and manufacturing method thereof
JP5816097B2 (en) 2009-01-22 2015-11-18 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー Stable growth hormone compound
WO2010087994A2 (en) 2009-01-30 2010-08-05 Whitehead Institute For Biomedical Research Methods for ligation and uses thereof
JP2012526840A (en) * 2009-05-13 2012-11-01 プロテイン デリヴァリー ソリューションズ エルエルシー Formulation system for transmembrane delivery
US20100310509A1 (en) * 2009-06-04 2010-12-09 Ash John D COMPOSITIONS COMPRISING MODULATORS OF SIGNAL TRANSDUCING RECEPTOR gp130 AND METHODS OF PRODUCING AND USING SAME
JP6086528B2 (en) 2009-08-06 2017-03-01 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー Growth hormone with long-term in vivo efficacy
CN118767117A (en) 2010-01-22 2024-10-15 诺沃—诺迪斯克保健股份有限公司 Growth hormone with prolonged effect in vivo
JP5980689B2 (en) 2010-01-22 2016-08-31 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー Stable growth hormone compound
EP2595661A1 (en) 2010-07-22 2013-05-29 Novo Nordisk Health Care AG Growth hormone conjugates
AU2012205718B2 (en) 2011-01-10 2017-07-06 The Regents Of The University Of Michigan Stem cell factor inhibitor
WO2012097256A1 (en) * 2011-01-14 2012-07-19 University Of Tennessee Research Foundation Therapeutic compositions and methods for disorders associated with neuronal degeneration
US10081684B2 (en) 2011-06-28 2018-09-25 Whitehead Institute For Biomedical Research Using sortases to install click chemistry handles for protein ligation
SG10201603411WA (en) * 2011-10-28 2016-07-28 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
ES2687801T3 (en) * 2013-03-29 2018-10-29 Glytech, Inc. Polypeptide presenting chains of sialylated sugars attached thereto
US11045523B2 (en) 2013-04-05 2021-06-29 Novo Nordisk Healthcare Ag Formulation of growth hormone albumin-binder conjugate
EP2986306A4 (en) 2013-04-18 2016-12-07 Armo Biosciences Inc Methods of using interleukin-10 for treating diseases and disorders
US20160068583A1 (en) * 2013-04-24 2016-03-10 Armo Biosciences, Inc. Interleukin-10 Compositions and Uses Thereof
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
ES2688206T3 (en) 2013-06-17 2018-10-31 Armo Biosciences, Inc. Procedure for assessing protein identity and stability
WO2015006554A1 (en) 2013-07-10 2015-01-15 The Regents Of The University Of Michigan Therapeutic antibodies and uses thereof
CN105658232A (en) 2013-08-30 2016-06-08 阿尔莫生物科技股份有限公司 Methods of using interleukin-10 for treating diseases and disorders
EP3068425B1 (en) 2013-11-11 2021-01-27 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
KR102230547B1 (en) * 2013-11-13 2021-03-22 수퍼랩 파 이스트 리미티드 Methods of determining interferon having direct inhibitory effects on tumors and uses thereof
UA119352C2 (en) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд COMBINATION OF LENALIDOMIDE OR POMALIDOMIDE AND STRUCTURES OF ANTI-CD38 ANTIBODY-ATHENED INTERPHERONE ALPHA-2B AND METHOD OF TREATMENT38
WO2015187295A2 (en) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Methods of lowering serum cholesterol
WO2016060996A2 (en) 2014-10-14 2016-04-21 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
AU2015336101A1 (en) 2014-10-22 2017-04-20 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
CA2965414C (en) 2014-10-29 2024-01-09 Teva Pharmaceuticals Australia Pty Ltd Interferon .alpha.2.beta. variants
US10618970B2 (en) 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
TWI728975B (en) * 2015-05-12 2021-06-01 英屬維爾京群島商遠東超級實驗室有限公司 Methods of determining interferon having direct inhibitory effects on tumors and uses thereof
CA2986755A1 (en) 2015-05-28 2016-12-01 Armo Biosciences, Inc. Pegylated interleukin-10 for use in treating cancer
US10398761B2 (en) 2015-08-25 2019-09-03 Armo Biosciences, Inc. Methods of using combinations of PEG-IL-10 and IL-15 for treating cancers
CA3019005A1 (en) 2016-05-18 2017-11-23 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
TW201808987A (en) * 2016-06-08 2018-03-16 健生生物科技公司 GM-CSF variants and methods of use
CN116970059A (en) 2016-12-22 2023-10-31 库尔生物制药有限公司 T cell modulating multimeric polypeptides and methods of use thereof
US11851471B2 (en) 2017-01-09 2023-12-26 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
BR112019018915A2 (en) 2017-03-15 2020-04-14 Pandion Therapeutics Inc targeted immunotolerance
IL269000B2 (en) 2017-03-15 2024-06-01 Cue Biopharma Inc Methods for modulating an immune response
US10926283B2 (en) 2017-04-12 2021-02-23 Carolyn S. Jordan Fingertip mist
JP2020521452A (en) 2017-05-24 2020-07-27 パンディオン・セラピューティクス・インコーポレイテッド Targeted tolerance
WO2019112852A1 (en) * 2017-12-06 2019-06-13 Pandion Therapeutics, Inc. Targeted immunotolerance
WO2019073315A1 (en) 2017-10-09 2019-04-18 Mansour Poorebrahim Interferon-beta analog peptide
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
WO2019139896A1 (en) 2018-01-09 2019-07-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
MX2021000801A (en) * 2018-07-24 2021-04-12 BioNTech SE IL2 AGONISTS.
EP3864045A2 (en) 2018-10-11 2021-08-18 Inhibrx, Inc. Dll3 single domain antibodies and therapeutic compositions thereof
WO2020077257A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. Pd-1 single domain antibodies and therapeutic compositions thereof
CA3115082A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. B7h3 single domain antibodies and therapeutic compositions thereof
WO2020076992A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. 5t4 single domain antibodies and therapeutic compositions thereof
CN111944036B (en) 2019-05-14 2024-09-06 上海盖浦生物科技有限公司 A mutant protein that proliferates immune cells
WO2020236875A1 (en) 2019-05-20 2020-11-26 Pandion Therapeutics, Inc. Madcam targeted immunotolerance
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
EP4132958A4 (en) * 2020-04-09 2024-05-15 United States Government as Represented by The Department of Veterans Affairs COMPOSITIONS CONTAINING RECOMBINANT EPO AND METHODS OF USE THEREOF
TW202208395A (en) 2020-05-12 2022-03-01 美商信號生物製藥公司 Multimeric t-cell modulatory polypeptides and methods of use thereof
EP4211149A4 (en) 2020-09-09 2024-10-09 Cue Biopharma, Inc. MHC CLASS II T-CELL MODULATING MULTIMER POLYPEPTIDES FOR THE TREATMENT OF TYPE 1 DIABETES MELLITUS (T1D) AND METHODS OF USE THEREOF
WO2022093671A1 (en) * 2020-10-26 2022-05-05 Partner Therapeutics, Inc. Granulocyte macrophage-colony stimulating factor mutants
CN116254253B (en) * 2022-11-11 2024-06-28 浙大宁波理工学院 A glutamate decarboxylase mutant obtained by DNA synthesis shuffling combined mutation and its application
WO2025136986A2 (en) 2023-12-18 2025-06-26 Genzyme Corporation Il-12 loss of potency muteins

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0240224A2 (en) * 1986-03-31 1987-10-07 Interferon Sciences, Inc. An alpha interferon analogue
WO2001025438A2 (en) * 1999-10-07 2001-04-12 Maxygen, Inc. Ifn-alpha homologues
WO2001061344A1 (en) * 2000-02-17 2001-08-23 California Institute Of Technology Computationally targeted evolutionary design

Family Cites Families (316)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US129584A (en) * 1872-07-16 Improvement in springs for gates and doors
US134351A (en) * 1872-12-31 Improvement in crutches
US129203A (en) * 1872-07-16 Improvement in animal-traps
US175694A (en) * 1876-04-04 Improvement in sponge-cups
US3171820A (en) 1964-02-17 1965-03-02 Scott Paper Co Reticulated polyurethane foams and process for their production
US3224404A (en) * 1964-11-06 1965-12-21 Jong George E De Mooring device
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
US4302386A (en) * 1978-08-25 1981-11-24 The Ohio State University Antigenic modification of polypeptides
US4363877B1 (en) * 1977-09-23 1998-05-26 Univ California Recombinant dna transfer vectors
US5221619A (en) * 1977-11-08 1993-06-22 Genentech, Inc. Method and means for microbial polypeptide expression
US4503035B1 (en) 1978-11-24 1996-03-19 Hoffmann La Roche Protein purification process and product
US4898830A (en) * 1979-07-05 1990-02-06 Genentech, Inc. Human growth hormone DNA
US4342832A (en) * 1979-07-05 1982-08-03 Genentech, Inc. Method of constructing a replicable cloning vehicle having quasi-synthetic genes
US5510472A (en) * 1979-11-21 1996-04-23 Yeda Research And Development Co. Ltd. Production of recombinant human interferon-beta2
US4816396A (en) * 1980-03-10 1989-03-28 Cetus Corporation Method and vector organism for controlled accumulation of heterologous gene products in bacillus subtilis
US6610830B1 (en) 1980-07-01 2003-08-26 Hoffman-La Roche Inc. Microbial production of mature human leukocyte interferons
US4462985A (en) 1980-08-22 1984-07-31 University Of Illinois Foundation Delivery of biologically active components of heterologous species interferon isolates
ES8302778A1 (en) 1980-11-10 1983-02-01 Genentech Inc A PROCEDURE FOR PRODUCING AN ANTI-VIRAL POLYPEPTIDE.
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4775622A (en) * 1982-03-08 1988-10-04 Genentech, Inc. Expression, processing and secretion of heterologous protein by yeast
US4446235A (en) * 1982-03-22 1984-05-01 Genentech, Inc. Method for cloning human growth hormone varient genes
US4665160A (en) * 1982-03-22 1987-05-12 Genentech, Inc. Novel human growth hormone like protein HGH-V encoded in the human genome
US4670393A (en) * 1982-03-22 1987-06-02 Genentech, Inc. DNA vectors encoding a novel human growth hormone-variant protein
DE3220116A1 (en) 1982-05-28 1983-12-01 Dr. Karl Thomae Gmbh, 7950 Biberach MICROBIOLOGICALLY MANUFACTURED (ALPHA) AND SS INTERFERONES, DNA SEQUENCES CODING FOR THESE INTERFERONES, MICROORGANISMS CONTAINING THIS GENETIC INFORMATION, AND METHOD FOR THE PRODUCTION THEREOF
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4588585A (en) * 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US5618697A (en) * 1982-12-10 1997-04-08 Novo Nordisk A/S Process for preparing a desired protein
US4497795A (en) 1982-12-13 1985-02-05 The Texas A&M University System Method of regulating appetite and efficiency of food utilization employing interferon
US4820515A (en) 1982-12-13 1989-04-11 Texas A&M University System Method of using interferon in low dosage to regulate appetite and efficiency of food utilization
US5910304A (en) 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
US4518584A (en) * 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4859600A (en) * 1983-04-25 1989-08-22 Genentech, Inc. Recombinant procaryotic cell containing correctly processed human growth hormone
US4755465A (en) * 1983-04-25 1988-07-05 Genentech, Inc. Secretion of correctly processed human growth hormone in E. coli and Pseudomonas
GB8317880D0 (en) 1983-07-01 1983-08-03 Searle & Co Structure and synthesis of interferons
US5198361A (en) * 1983-07-15 1993-03-30 Bio-Technology General Corp. Plasmids for production of met-asp-gln bovine growth hormone, hosts containing the plasmids, products manufactured thereby and related methods
US5256546A (en) * 1983-07-15 1993-10-26 Bio-Technology General Corp. Bacterial expression of porcine growth hormone
BG49718A3 (en) * 1983-07-15 1992-01-15 Bio- Technology General Corp METHOD FOR OBTAINING A POLYPEPTIDE WITH SUPEROXIDE DISMUTASE ACTIVITY
US5637495A (en) * 1983-07-15 1997-06-10 Bio-Technology General Corp. Plasmids for production of human growth hormone or polypeptide analog thereof, hosts containing the plasmids, products manufactured thereby, and related methods
US5670371A (en) * 1983-07-15 1997-09-23 Bio-Technology General Corp. Bacterial expression of superoxide dismutase
NZ210501A (en) * 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
KR850004274A (en) * 1983-12-13 1985-07-11 원본미기재 Method for preparing erythropoietin
US4703008A (en) * 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
EP0146903A3 (en) 1983-12-19 1987-07-22 Schering Corporation Production of a vector encoding a novel hybrid interferon species
GB8412564D0 (en) * 1984-05-17 1984-06-20 Searle & Co Structure and properties
US4747825A (en) * 1984-06-29 1988-05-31 Ferring Laboratories, Inc. Apparatus and methodology for pulsed administration of growth promoting agents
US4937076A (en) 1984-08-10 1990-06-26 Combe Incorporated Chewable aspirin and buffering material tablet and method for producing same
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
GB2183661B (en) 1985-03-30 1989-06-28 Marc Ballivet Method for obtaining dna, rna, peptides, polypeptides or proteins by means of a dna recombinant technique
US5198345A (en) 1985-04-15 1993-03-30 Gist-Brocades N.V. Vectors in use in filamentous fungi
US4845196A (en) * 1985-06-24 1989-07-04 G. D. Searle & Co. Modified interferon gammas
US5391485A (en) * 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US5631227A (en) * 1985-09-18 1997-05-20 The Upjohn Company Somatotropin analogs
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
IL77186A0 (en) * 1985-11-29 1986-04-29 Touitou Elka Pharmaceutical insulin composition
US5298603A (en) * 1985-12-21 1994-03-29 Hoechst Aktiengesellschaft GM-CSF protein, its derivatives, the preparation of proteins of this type, and their use
US4820514A (en) 1985-12-30 1989-04-11 Texas A&M University System Low dosage of interferon to enhance vaccine efficiency
US6548640B1 (en) * 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US4959217A (en) * 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
DK173067B1 (en) * 1986-06-27 1999-12-13 Univ Washington Human erythropoietin gene, method of expression thereof in transfected cell lines, the transfected cell lines
EP0260350B1 (en) 1986-09-05 1992-02-12 Cetus Oncology Corporation Oxidation-resistant interferon-beta muteins and their production; formulations containing such muteins
US5183746A (en) 1986-10-27 1993-02-02 Schering Aktiengesellschaft Formulation processes for pharmaceutical compositions of recombinant β-
ZA878295B (en) 1986-11-06 1988-05-03 Amarillo Cell Culture Co. Inc. Treatment of immuno-resistant disease
CA1320905C (en) 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
US5013718A (en) * 1986-11-21 1991-05-07 Amgen, Inc. Method for treating iron overload using EPO
US5214132A (en) * 1986-12-23 1993-05-25 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
US4835260A (en) * 1987-03-20 1989-05-30 Genetics Institute, Inc. Erythropoietin composition
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5017371A (en) 1988-01-06 1991-05-21 Amarillo Cell Culture Company, Incorporated Method for reducing side effects of cancer therapy
US5698418A (en) * 1988-02-17 1997-12-16 Pharmacia & Upjohn Company Fermentation media and methods for controlling norleucine in polypeptides
US5068317A (en) * 1988-03-15 1991-11-26 Eli Lilly And Company Novel derivative of human growth hormone
US5445826A (en) * 1988-06-28 1995-08-29 Cibus Pharmaceutical, Inc. Delivery system containing a gel-forming dietary fiber and a drug
CA1333777C (en) * 1988-07-01 1995-01-03 Randy M. Berka Aspartic proteinase deficient filamentous fungi
US5079345A (en) * 1988-08-19 1992-01-07 Eli Lilly And Company Proteins having growth hormone anabolic properties with reduced effect on carbohydrate metabolism
ATE198353T1 (en) * 1988-08-24 2001-01-15 American Cyanamid Co STABILIZATION OF SOMATOTROPINES THROUGH MODIFICATION OF CYSTEIN RESIDUE THROUGH SITE-SPECIFIC MUtagenesis OR CHEMICAL DERIVATIZATION
US5130422A (en) * 1988-08-29 1992-07-14 Monsanto Company Variant somatotropin-encoding DNA
US5089473A (en) * 1988-08-29 1992-02-18 Monsanto Company Somatotropin variants and their use
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5079230A (en) * 1988-09-12 1992-01-07 Pitman-Moore, Inc. Stable bioactive somatotropins
GB8824591D0 (en) * 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
US5688666A (en) * 1988-10-28 1997-11-18 Genentech, Inc. Growth hormone variants with altered binding properties
EP0397834B1 (en) * 1988-10-28 2000-02-02 Genentech, Inc. Method for identifying active domains and amino acid residues in polypeptides and hormone variants
US6780613B1 (en) * 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
US5534617A (en) * 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5101018A (en) * 1989-06-12 1992-03-31 International Minerals & Chemical Corp. Method for recovering recombinant proteins
US5663305A (en) * 1989-07-10 1997-09-02 The Upjohn Company Somatotropin analogs
DE3923963A1 (en) * 1989-07-20 1991-01-31 Behringwerke Ag MUTEINE OF HUMAN ERYTHROPOETIN, THEIR PRODUCTION AND THEIR USE
NZ234674A (en) 1989-08-02 1992-02-25 Seragen Inc Mutant interleukin-2,dna encoding it, host cells, cytotoxic and toxin-mutant il-2 conjugates
US5047511A (en) * 1989-08-28 1991-09-10 Pitman-Moore, Inc. Method for recovering recombinant proteins
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US6787336B1 (en) * 1989-10-12 2004-09-07 Ohio University/Edison Biotechnology Institute DNA encoding growth hormone antagonists
US6583115B1 (en) * 1989-10-12 2003-06-24 Ohio University/Edison Biotechnology Institute Methods for treating acromegaly and giantism with growth hormone antagonists
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US5958879A (en) * 1989-10-12 1999-09-28 Ohio University/Edison Biotechnology Institute Growth hormone receptor antagonists and methods of reducing growth hormone activity in a mammal
US5856298A (en) * 1989-10-13 1999-01-05 Amgen Inc. Erythropoietin isoforms
JPH03151399A (en) 1989-11-07 1991-06-27 Snow Brand Milk Prod Co Ltd Mutant human erythropoietin
WO1991010684A1 (en) * 1990-01-08 1991-07-25 Schering Corporation Oxidized variants of gm-csf
US5109121A (en) * 1990-01-22 1992-04-28 Pitman-Moore, Inc. Method for recovering recombinant proteins
US4988798A (en) * 1990-01-22 1991-01-29 Pitman-Moore, Inc. Method for recovering recombinant proteins
US5262568A (en) 1990-03-02 1993-11-16 State Of Oregon Tri- and tetra-substituted guanidines and their use as excitatory amino acid antagonists
ES2078518T3 (en) 1990-04-05 1995-12-16 Roberto Crea COMPLETE DISPLACEMENT MUTAGENESIS.
GB9107846D0 (en) * 1990-04-30 1991-05-29 Ici Plc Polypeptides
US5951972A (en) * 1990-05-04 1999-09-14 American Cyanamid Company Stabilization of somatotropins and other proteins by modification of cysteine residues
US5399345A (en) * 1990-05-08 1995-03-21 Boehringer Mannheim, Gmbh Muteins of the granulocyte colony stimulating factor
WO1991018927A1 (en) 1990-06-04 1991-12-12 Schering Corporation Method for preparing interferon alpha-2 crystals
US5849694A (en) * 1990-07-16 1998-12-15 Synenki; Richard M. Stable and bioactive modified porcine somatotropin and pharmaceutical compositions thereof
IE912365A1 (en) * 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
US6258530B1 (en) 1990-09-28 2001-07-10 Ixsys, Inc. Surface expression libraries of randomized peptides
US5770434A (en) 1990-09-28 1998-06-23 Ixsys Incorporated Soluble peptides having constrained, secondary conformation in solution and method of making same
US5871974A (en) 1990-09-28 1999-02-16 Ixsys Inc. Surface expression libraries of heteromeric receptors
US5215741A (en) 1990-10-30 1993-06-01 Amarillo Cell Culture Company, Incorporated Method for prevention of parasite infections
CA2044468C (en) * 1990-11-21 2006-08-22 Richard A. Nash Canine granulocyte macrophage colony stimulating factor
US5310882A (en) * 1990-11-30 1994-05-10 American Cyanamid Company Somatotropins with alterations in the α-helix 3 region
NZ240718A (en) * 1990-11-30 1996-10-28 Bio Technology General Corp Somatotropin analogues carrying mutations in the alpha-helix-1 region
CA2405246A1 (en) * 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
EP0499990B1 (en) * 1991-02-19 1996-05-15 Takeda Chemical Industries, Ltd. Method for producing cysteine-free peptides
JP3417558B2 (en) * 1991-05-10 2003-06-16 ジェネンテク，インコーポレイテッド Choice of ligand agonists and antagonists
US5733761A (en) * 1991-11-05 1998-03-31 Transkaryotic Therapies, Inc. Protein production and protein delivery
NZ245015A (en) * 1991-11-05 1995-12-21 Transkaryotic Therapies Inc Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production
DE69324671D1 (en) 1992-02-10 1999-06-02 Interferon Sciences Inc IMPROVED ALPHA INTERFERON COMPOSITION AND METHOD FOR THE PRODUCTION THEREOF FROM LEUKOCYTES OF THE HUMAN PERIPHERAL BLOOD
US5676942A (en) * 1992-02-10 1997-10-14 Interferon Sciences, Inc. Composition containing human alpha interferon species proteins and method for use thereof
JPH05289267A (en) * 1992-04-07 1993-11-05 Fuji Photo Film Co Ltd Silver halide color photographic sensitive material
US5614184A (en) * 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
US6153407A (en) * 1992-07-28 2000-11-28 Beth Israel Deaconess Medical Center Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics
US6436387B1 (en) * 1992-11-24 2002-08-20 G.D. Searle & Co. Methods of ex-vivo expansion of hematopoietic cells using multivariant IL-3 hematopoiesis chimera proteins
US5581476A (en) * 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
US5441734A (en) 1993-02-25 1995-08-15 Schering Corporation Metal-interferon-alpha crystals
HUT73876A (en) * 1993-04-29 1996-10-28 Abbott Lab Erythropoietin analog compositions and methods
EP0626448A3 (en) 1993-05-26 1998-01-14 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Process for preparing and purifying alpha-interferon
US6299870B1 (en) 1993-06-11 2001-10-09 Pbl Biomedical Laboratories Mutant human interferons
US5789551A (en) 1993-06-11 1998-08-04 Pestka Biomedical Laboratories, Inc. Human leukocyte interferon Hu-IFN-α001
NZ269766A (en) * 1993-07-28 1998-01-26 Medvet Science Pty Ltd Haemopoietic growth factor antagonists; relates to modified forms of such factors
US5424289A (en) * 1993-07-30 1995-06-13 Alza Corporation Solid formulations of therapeutic proteins for gastrointestinal delivery
US5798500A (en) * 1993-08-10 1998-08-25 Stillwagon, Jr.; Ross I. Curling iron stove with internal cavity with electric heater positioned therebelow
CN1057534C (en) 1993-08-17 2000-10-18 柯瑞英-艾格公司 Erythropoietin analogs
US5976552A (en) * 1995-04-28 1999-11-02 Protein Sciences Corporation Virus vaccines
EP0749980A4 (en) * 1993-12-29 1999-09-29 Sumitomo Pharma NEW HUMAN CILIARY NEUROTROPHIC FACTOR
US5597709A (en) * 1994-01-27 1997-01-28 Human Genome Sciences, Inc. Human growth hormone splice variants hGHV-2(88) and hGHV-3(53)
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6165793A (en) 1996-03-25 2000-12-26 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US6335160B1 (en) 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
ES2312166T3 (en) * 1994-02-23 2009-02-16 Kyowa Hakko Kogyo Co., Ltd PLAQUETARY GROWTH ACCELERATOR.
EP0748338A4 (en) 1994-03-04 2001-03-28 Merck & Co Inc AFFINITY IN VITRO ANTIBODY MATURATION USING ALANINE SCAN MUTAGENESIS
US5545723A (en) 1994-03-15 1996-08-13 Biogen Inc. Muteins of IFN-β
US5747446A (en) * 1994-03-22 1998-05-05 Beth Israel Deaconess Medical Center Modified polypeptides with increased biological activity
US5580853A (en) * 1994-03-22 1996-12-03 New England Deaconess Hospital Modified polypeptides with increased biological activity
US6024734A (en) 1994-03-31 2000-02-15 Brewitt; Barbara A. Treatment methods using homeopathic preparations of growth factors
US5635599A (en) * 1994-04-08 1997-06-03 The United States Of America As Represented By The Department Of Health And Human Services Fusion proteins comprising circularly permuted ligands
US6346243B1 (en) 1994-04-12 2002-02-12 Research Development Foundation Inhibition of transplant rejection by type one interferon
JP3560639B2 (en) 1994-05-26 2004-09-02 株式会社タカハシキカン Incinerator
FR2722208B1 (en) 1994-07-05 1996-10-04 Inst Nat Sante Rech Med NEW INTERNAL RIBOSOME ENTRY SITE, VECTOR CONTAINING SAME AND THERAPEUTIC USE
US5460232A (en) * 1994-07-25 1995-10-24 Central Mine Equipment Company Rotary earth drill bit socket shield
US6099830A (en) * 1994-08-09 2000-08-08 Zymogenetics, Inc. Methods for stimulating erythropoiesis using hematopoietic proteins
IL116085A (en) * 1994-12-16 1999-12-31 Ortho Pharma Corp Spray dried erythropoietin
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US6387365B1 (en) 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
US5814485A (en) 1995-06-06 1998-09-29 Chiron Corporation Production of interferon-β (IFN-β) in E. coli
US5871723A (en) 1995-06-06 1999-02-16 The Regent Of The University Of Michigan CXC chemokines as regulators of angiogenesis
US5854049A (en) * 1995-06-09 1998-12-29 President And Fellows Of Harvard College Plasmin-resistant streptokinase
AUPN378095A0 (en) * 1995-06-23 1995-07-20 Bresagen Limited Haemopoietic growth factor antagonists and uses therefor
NZ286884A (en) * 1995-06-29 1997-12-19 Mitsui Chemicals Inc Use of 20 kd human growth hormone in hrt, increasing serum igf-1 levels and stimulating lipolysis
US6057103A (en) 1995-07-18 2000-05-02 Diversa Corporation Screening for novel bioactivities
DE19535853C2 (en) * 1995-09-18 1999-04-01 Fraunhofer Ges Forschung Variants of recombinant human interferon gamma, process for their preparation and their use
CA2230492C (en) * 1995-09-21 2009-05-26 Genentech, Inc. Human growth hormone variants
PT858343E (en) 1995-11-02 2004-07-30 Schering Corp THERAPY FOR CONTINUOUS INFUSE OF A LOW DOSE OF CYTOKINE
US6479258B1 (en) 1995-12-07 2002-11-12 Diversa Corporation Non-stochastic generation of genetic vaccines
US6238884B1 (en) 1995-12-07 2001-05-29 Diversa Corporation End selection in directed evolution
US6171820B1 (en) 1995-12-07 2001-01-09 Diversa Corporation Saturation mutagenesis in directed evolution
US20030215798A1 (en) 1997-06-16 2003-11-20 Diversa Corporation High throughput fluorescence-based screening for novel enzymes
CA2244372A1 (en) 1996-01-23 1997-07-31 Marc S. Collett Methods for identifying inhibitors of rna viruses
DE69712124T2 (en) * 1996-02-13 2002-12-12 Jcr Pharmaceutical Co., Ltd. Hormones de croissance humaines mutantes et leur utilization
DE69706657T2 (en) 1996-02-28 2002-06-20 Unihart Corp., Dublin PHARMACEUTICAL COMPOSITIONS CONTAINING NATURAL HUMAN ALPHA INTERFERON
US6096548A (en) 1996-03-25 2000-08-01 Maxygen, Inc. Method for directing evolution of a virus
SI9720025A (en) * 1996-03-29 1999-08-31 Emishphere Technologies, Inc. Compounds and compositions for delivering active agents
US6204022B1 (en) 1996-04-12 2001-03-20 Pepgen Corporation And University Of Florida Low-toxicity human interferon-alpha analogs
CA2251738A1 (en) 1996-04-16 1997-10-23 Immusol Incorporated Targeted viral vectors
CA2253971A1 (en) 1996-05-09 1997-11-13 Pharma Pacific Pty.Ltd. Use of high dose interferon by oralmucosal contact to treat viral infections and neoplastic conditions
CN1151840C (en) 1996-05-09 2004-06-02 太平洋制药控股公司 Stimulation of host defence mechanisms against tumors
US6207145B1 (en) 1997-05-09 2001-03-27 Pharma Pacific Pty Ltd. Therapeutic applications of high dose interferon
US5763239A (en) 1996-06-18 1998-06-09 Diversa Corporation Production and use of normalized DNA libraries
CA2269654A1 (en) * 1996-08-23 1998-02-26 Arch Development Corporation Long-term expression of gene products by transforming muscle cells
JP2001504325A (en) 1996-09-27 2001-04-03 マキシジェン，インコーポレイテッド A method for optimization of gene therapy by recursive sequence shuffling and selection
US6967092B1 (en) * 1996-10-25 2005-11-22 Mc Kearn John P Multi-functional chimeric hematopoietic receptor agonists
DE19648625A1 (en) * 1996-11-13 1998-05-14 Soft Gene Gmbh Microprojectile for the introduction of substances into cells by ballistic transfer
US5862514A (en) 1996-12-06 1999-01-19 Ixsys, Inc. Method and means for synthesis-based simulation of chemicals having biological functions
BR9606270A (en) 1996-12-18 1998-09-22 Univ Minas Gerais Process for the production of recombinant human beta-cis interferon protein and recombinant human beta-cis interferon protein
US6884419B1 (en) * 1996-12-23 2005-04-26 Kyowa Hakko Kogyo, Co., Ltd. hG-CSF fusion polypeptide having c-mpl activity, DNA coding for same and methods of treating anemia using same
CA2278734A1 (en) 1997-01-23 1998-07-30 Immusol Incorporated Gene functional analysis and discovery using randomized or target-specific ribozyme gene vector libraries
US5779434A (en) 1997-02-06 1998-07-14 Baker Hughes Incorporated Pump mounted thrust bearing
DE19717864C2 (en) 1997-04-23 2001-05-17 Fraunhofer Ges Forschung Human recombinant interferon beta, process for its preparation and its use
US6153420A (en) * 1997-04-24 2000-11-28 Zymogenetics, Inc. Serine protease polypeptides and materials and methods for making them
EP0982029A4 (en) * 1997-05-08 2002-07-03 Chugai Pharmaceutical Co Ltd PROPHYLACTIC AND THERAPEUTIC AGENTS AGAINST ARTERIOSCLEROSIS
EP1173191A4 (en) * 1997-05-13 2004-12-01 Univ California NOVEL ANTI-ANGIOGENIC PEPTIDE AGENTS, USE OF THE SAME FOR THERAPY AND DIAGNOSIS
US6165476A (en) * 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
US7270809B2 (en) 1997-07-14 2007-09-18 Bolder Biotechnology, Inc. Cysteine variants of alpha interferon-2
ATE375363T1 (en) * 1997-07-14 2007-10-15 Bolder Biotechnology Inc GROWTH HORMONE DERIVATIVES AND RELATED PROTEINS
US6753165B1 (en) * 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US7153943B2 (en) * 1997-07-14 2006-12-26 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins, and methods of use thereof
US6037177A (en) 1997-08-08 2000-03-14 Cell Genesys, Inc. Method for increasing the efficiency of recombinant AAV production
JP2001514845A (en) 1997-09-05 2001-09-18 ターゲティッド ジェネティクス コーポレイション Method for generating a high titer helper-free preparation of a recombinant AAV vector
US6737407B1 (en) * 1997-09-08 2004-05-18 Metabolic Pharmaceuticals, Ltd. Treatment of obesity
US6156509A (en) 1997-11-12 2000-12-05 Genencor International, Inc. Method of increasing efficiency of directed evolution of a gene using phagemid
US6897297B1 (en) 1997-12-03 2005-05-24 Curis, Inc. Hydrophobically-modified protein compositions and methods
US6165458A (en) 1997-12-26 2000-12-26 Pharmaderm Laboratories Ltd. Composition and method for dermal and transdermal administration of a cytokine
US6274158B1 (en) * 1998-02-04 2001-08-14 Veronica L. Zaharia Czeizler Treatment with recombinant human erythropoietin of bleeding in patients with normal and abnormal hemostasis
SI0937456T1 (en) * 1998-02-23 2004-12-31 Cilag Ag International Erythropoietin liposomal dispersion
US6036949A (en) 1998-03-05 2000-03-14 Amarillo Biosciences, Inc. Treatment of fibromyalgia with low doses of interferon
US6676937B1 (en) * 1998-03-09 2004-01-13 Caritas St. Elizabeth's Medical Center Of Boston Inc. Compositions and methods for modulating vascularization
US20040228834A1 (en) * 1998-03-09 2004-11-18 Jeffrey Isner Compositions and methods for modulating vascularization
US6174406B1 (en) * 1998-04-09 2001-01-16 International Business Machines Corporation Bonding together surfaces
US6413776B1 (en) 1998-06-12 2002-07-02 Galapagos Geonomics N.V. High throughput screening of gene function using adenoviral libraries for functional genomics applications
ATE339507T1 (en) * 1998-06-15 2006-10-15 Gtc Biotherapeutics Inc ERYTHROPOIETIN ANALOG HUMAN SERUM-ALBUMIN FUSION PROTEIN
US6472512B1 (en) 1998-07-21 2002-10-29 Human Genome Sciences, Inc. Keratinocyte derived interferon
DK1121382T3 (en) 1998-10-16 2006-11-13 Biogen Idec Inc Interferon-beta fusion proteins and their applications
DK1656952T3 (en) * 1998-10-16 2014-01-20 Biogen Idec Inc Polyalkylene glycol conjugates of interferon beta-1A and applications thereof
AUPP660698A0 (en) * 1998-10-21 1998-11-12 University Of Queensland, The A method of protein engineering
AU763929B2 (en) 1998-11-25 2003-08-07 Amarillo Biosciences, Inc. Interferon-alpha mediated upregulation of aquaporin expression
WO2000032772A2 (en) * 1998-11-30 2000-06-08 Eli Lilly And Company Erythropoietic compounds
US6171620B1 (en) * 1999-04-27 2001-01-09 Health Research, Inc. Method of enhancing the efficacy of anti-tumor agents
US6555343B1 (en) * 1999-05-07 2003-04-29 Genentech Inc. Chimpanzee erythropoietin (CHEPO) polypeptides and nucleic acids encoding the same
US6831060B2 (en) * 1999-05-07 2004-12-14 Genentech, Inc. Chimpanzee erythropoietin (CHEPO) polypeptides and nucleic acids encoding the same
US6946265B1 (en) * 1999-05-12 2005-09-20 Xencor, Inc. Nucleic acids and proteins with growth hormone activity
US6514729B1 (en) * 1999-05-12 2003-02-04 Xencor, Inc. Recombinant interferon-beta muteins
US6710025B1 (en) * 1999-05-26 2004-03-23 The Brigham And Women's Hospital, Inc. Treatment of damaged tissue using agents that modulate the activity of alpha-smooth muscle actin
US6319691B1 (en) * 1999-06-15 2001-11-20 Usa Universe Bioengineering, Inc. Fusion proteins comprising IFN-alpha2b and TM-alpha1
US6566329B1 (en) * 1999-06-28 2003-05-20 Novo Nordisk A/S Freeze-dried preparation of human growth hormone
CZ299516B6 (en) * 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Erythropoietin glycoprotein conjugate, process for its preparation and use and pharmaceutical composition containing thereof
KR100356140B1 (en) * 1999-07-08 2002-10-19 한미약품공업 주식회사 Modified Human Granulocyte-Colony Stimulating Factor and Process for Producing Same
US6531122B1 (en) * 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
US7144574B2 (en) * 1999-08-27 2006-12-05 Maxygen Aps Interferon β variants and conjugates
JP2003510295A (en) 1999-09-28 2003-03-18 アマリロ バイオサイエンシズ，インコーポレイテッド Low dose IFN gamma for the treatment of disease
US6627617B1 (en) 1999-10-01 2003-09-30 University Of North Carolina At Chapel Hill Temperature-sensitive regulation of viral vector production
US20040002474A1 (en) 1999-10-07 2004-01-01 Maxygen Inc. IFN-alpha homologues
AU1436401A (en) 1999-10-21 2001-05-14 Board Of Trustees Of The University Of Arkansas, The RepO-associated virus AAV REP78 major regulatory protein, mutants thereof and uses thereof
AU7646200A (en) 1999-11-05 2001-05-14 Novozymes A/S Microtiter plate (mtp) based high throughput screening (hts) assays
SK8292002A3 (en) * 1999-11-12 2002-12-03 Maxygen Holdings Ltd A conjugate exhibiting interferon gamma activity, nucleotide sequence encoding for a polypeptide fraction of conjugate, an expression vector and a host cell containing nucleotide sequence, pharmaceutical composition comprising the same and use thereof
EP1237567B1 (en) 1999-12-09 2005-08-03 Chiron Corporation Method for administering a cytokine to the central nervous system and the lymphatic system
FR2802645B1 (en) 1999-12-16 2002-03-08 Meillat Roland METHOD FOR EVALUATING THE PERFORMANCE OF A SET OF BIOLOGICAL AGENTS IN LIVE TARGET CELLS AND ITS APPLICATIONS
US6646110B2 (en) * 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates
US6555660B2 (en) * 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
AU780270B2 (en) * 2000-02-23 2005-03-10 Association Francaise Contre Les Myopathies Treatment of immune diseases
FR2808804B1 (en) * 2000-05-09 2002-08-02 Nautilus Biotech METHOD FOR DETERMINING THE TITLE OF BIOLOGICAL AGENTS IN REAL TIME IN LIVING TARGET CELLS AND ITS APPLICATIONS
BR0110756A (en) * 2000-05-12 2003-07-08 Univ Wales Medicine Detection method for detecting a variation in gh1 effective to act as an indicator of gh dysfunction in an individual, gh1 variant, protein or amino acid sequence, human gh variant, screening method for screening an individual suspected of having gh1 dysfunction. gh, kit, isolated, purified or recombinant nucleic acid sequence, vector, host cell, process for preparing a gh variant, amino acid sequence, composition, and use of gh1 variant or gh variant
IL152804A0 (en) * 2000-05-16 2003-06-24 Bolder Biotechnology Inc Methods for refolding proteins containing free cysteine residues
US7154958B2 (en) * 2000-07-05 2006-12-26 Texas Instruments Incorporated Code division multiple access wireless system with time reversed space time block transmitter diversity
EP1305437B1 (en) 2000-07-31 2010-09-01 Biolex Therapeutics, Inc. Expression of biologically active polypeptides in duckweed
JP4707931B2 (en) 2000-08-18 2011-06-22 エミスフェアー・テクノロジーズ・インク Active agent delivery compounds and compositions
WO2002015664A2 (en) 2000-08-23 2002-02-28 The New York Hospital Medical Center Of Queens Methods of preventing or treating west nile virus and other infections
FR2813314B1 (en) 2000-08-25 2004-05-07 Biomethodes MASSIVE DIRECTED MUTAGENESIS PROCESS
JP4799803B2 (en) * 2000-09-08 2011-10-26 マサチューセッツ インスティテュート オブ テクノロジー G-CSF analog compositions and methods
US20020169290A1 (en) 2000-11-02 2002-11-14 Claus Bornaes New multimeric interferon beta polypeptides
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US20060183197A1 (en) * 2001-01-11 2006-08-17 Andersen Kim V Variant growth hormone molecules conjugated with macromolecules compounds
WO2002077034A2 (en) * 2001-02-06 2002-10-03 Merk Patent Gmbh Modified granulocyte colony stimulating factor (g-csf) with reduced immunogenicity
BR0207015A (en) * 2001-02-06 2004-07-06 Merck Patent Ges Mit Beschroen Modified erythropoientin (epo) with reduced immunogenicity
US7189830B2 (en) * 2001-02-19 2007-03-13 Merck Patent Gmbh Anti-KSA/IL-2 fusion proteins with reduced immunogenicity
CA2439690A1 (en) 2001-03-02 2002-10-31 Merck Patent Gesellschaft Mit Beschraenkter Haftung Modified interferon alpha with reduced immunogenicity
MXPA03008032A (en) * 2001-03-08 2003-12-04 Merck Patent Gmbh Modified granulocyte macrophage colony stimulating factor (gm-csf) with reduced immunogenicity.
EP1368377A2 (en) 2001-03-15 2003-12-10 MERCK PATENT GmbH Modified interferon beta with reduced immunogenicity
WO2002079415A2 (en) * 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
FR2823220B1 (en) * 2001-04-04 2003-12-12 Genodyssee NOVEL ERYTHROPOIETIN (EPO) POLYNUCLEOTIDES AND POLYPEPTIDES
WO2002092619A2 (en) * 2001-05-14 2002-11-21 The Gouvernment Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified growth hormone
US6833351B2 (en) * 2001-05-21 2004-12-21 Douglas T. Dieterich Method of treating anemia caused by ribavirin treatment of hepatitis C using erythropoietin alpha
US6828305B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7647184B2 (en) 2001-08-27 2010-01-12 Hanall Pharmaceuticals, Co. Ltd High throughput directed evolution by rational mutagenesis
US20030129203A1 (en) 2001-08-27 2003-07-10 Nautilus Biotech S.A. Mutant recombinant adeno-associated viruses
EP1427756A1 (en) * 2001-09-04 2004-06-16 MERCK PATENT GmbH Modified human growth hormone
CA2403372A1 (en) * 2001-09-13 2003-03-13 Intier Automotive Inc. Second row fold and pivot seat assembly
US6930086B2 (en) * 2001-09-25 2005-08-16 Hoffmann-La Roche Inc. Diglycosylated erythropoietin
EP2042196B1 (en) * 2001-10-10 2016-07-13 ratiopharm GmbH Remodelling and glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF)
US6786634B2 (en) * 2001-10-10 2004-09-07 Noritake Co., Limited Temperature measuring method and apparatus
AU2002326961A1 (en) * 2001-10-10 2003-04-22 Centocor, Inc. Nucleic acid vaccines using tumor antigen encoding nucleic acids with cytokine adjuvant encoding nucleic acid
US7297511B2 (en) 2001-10-10 2007-11-20 Neose Technologies, Inc. Interferon alpha: remodeling and glycoconjugation of interferon alpha
US20030170679A1 (en) * 2001-11-09 2003-09-11 Wood Linda Susan Single nucleotide polymorphisms in GH-1
GB0127213D0 (en) * 2001-11-12 2002-01-02 Univ Wales Medicine Method of detecting growth hormone variations in humans the variations and their uses
GB2389115B (en) * 2001-12-14 2005-03-16 Asterion Ltd Polypeptide having a plurality of modified growth hormone receptor binding domains of growth hormone
US20030224404A1 (en) 2002-02-25 2003-12-04 Manuel Vega High throughput directed evolution of nucleic acids by rational mutagenesis
CA2491567A1 (en) * 2002-07-01 2004-01-08 The Kenneth S. Warren Institute, Inc. Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs
US6809191B2 (en) * 2002-07-03 2004-10-26 Vaxim, Inc. GM-CSF nucleic acid sequences
WO2004018515A2 (en) * 2002-08-09 2004-03-04 Merck Patent Gmbh T-cell epitopes in erythropoietin
EP1549675B1 (en) 2002-08-31 2008-02-13 CJ Corp Glycosylated human interferon alpha isoform
EP1539950A1 (en) 2002-09-09 2005-06-15 Nautilus Biotech Rational directed protein evolution using two-dimensional rational mutagenesis scanning
US20060020396A1 (en) 2002-09-09 2006-01-26 Rene Gantier Rational directed protein evolution using two-dimensional rational mutagenesis scanning
US20050202438A1 (en) 2002-09-09 2005-09-15 Rene Gantier Rational directed protein evolution using two-dimensional rational mutagenesis scanning
DE60332358D1 (en) * 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd PROTEASE-RESISTANT MODIFIED INTERFERON ALPHA POLYPEPTIDE
US20050176627A1 (en) * 2002-09-09 2005-08-11 Anthony Cerami Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin
AU2003277088A1 (en) 2002-10-01 2004-04-23 Xencor, Inc Interferon variants with improved properties
US20050054053A1 (en) * 2002-10-01 2005-03-10 Xencor, Inc. Interferon variants with improved properties
US7189740B2 (en) * 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US20040091961A1 (en) * 2002-11-08 2004-05-13 Evans Glen A. Enhanced variants of erythropoietin and methods of use
EP1565205A4 (en) 2002-11-18 2006-07-05 Maxygen Inc INTERFERON-ALPHA POLYPEPTIDES AND CONJUGATES
US20040142870A1 (en) * 2002-11-20 2004-07-22 Finn Rory F. N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof
TWI281864B (en) * 2002-11-20 2007-06-01 Pharmacia Corp N-terminally monopegylated human growth hormone conjugates and process for their preparation
WO2004074486A2 (en) 2003-02-18 2004-09-02 Merck Patent Gmbh Fusion proteins of interferon alpha muteins with improved properties
KR100541850B1 (en) 2003-03-31 2006-01-11 삼성정밀화학 주식회사 Human Interferon-beta Variants and Methods for Making the Same
WO2005003157A2 (en) 2003-06-10 2005-01-13 Xencor, Inc. Interferon variants with improved properties
KR100632985B1 (en) * 2003-07-26 2006-10-11 메덱스젠 주식회사 Methods for Enhancing the Potency of Bioactive Regulatory Proteins and Exemplary Variants
US7338933B2 (en) * 2004-01-08 2008-03-04 Neose Technologies, Inc. O-linked glycosylation of peptides
EP2327724A3 (en) * 2004-02-02 2011-07-27 Ambrx, Inc. Modified human growth hormone polypeptides and their uses
JP2008508854A (en) 2004-04-23 2008-03-27 ケンブリッジ アンティボディー テクノロジー リミテッド Erythropoietin protein variant
CA2565368A1 (en) 2004-04-29 2005-11-24 Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. Oral formulations comprising bone morphogenetic proteins for treating metabolic bone diseases
CA2576030A1 (en) 2004-08-09 2006-02-23 Alios Biopharma Inc. Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same
US20060073563A1 (en) 2004-09-02 2006-04-06 Xencor, Inc. Erythropoietin derivatives with altered immunogenicity
NZ553809A (en) 2004-09-03 2010-03-26 Creabilis Therapeutics Spa Use of polypeptides obtained through systematic mutations of single amino acids of human and non-human box-A of HMGB1 to prevent and/or antagonize pathologies induced by HMGB1
US7998930B2 (en) * 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
GB0500099D0 (en) 2005-01-05 2005-02-09 Cambridge Antibody Tech Methods and means relating to protein variants
EP1877434A2 (en) 2005-05-04 2008-01-16 Nautilus Biotech Modified interferon-gamma polypeptides and methods for using modified interferon-gamma polypeptides
WO2007110230A2 (en) 2006-03-27 2007-10-04 Institut Pasteur Secreted proteins as early markers and drug targets for autoimmunity, tumorigenesis and infections
US20080038224A1 (en) * 2006-03-28 2008-02-14 Thierry Guyon Modified interferon-beta (IFN-beta) polypeptides
EP2423305A1 (en) 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modified coagulation factor IX polypeptides and use thereof for treatment
CN101678079B (en) 2006-11-28 2013-12-25 韩诺生物制约株式会社 Modified erythropoietin polypeptides and uses thereof for treatment
US20080260820A1 (en) 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
US20120264686A9 (en) 2008-05-29 2012-10-18 Hanall Biopharma Co. Ltd Modified erythropoietin (epo) polypeptides that exhibit increased protease resistance and pharmaceutical compositions thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0240224A2 (en) * 1986-03-31 1987-10-07 Interferon Sciences, Inc. An alpha interferon analogue
WO2001025438A2 (en) * 1999-10-07 2001-04-12 Maxygen, Inc. Ifn-alpha homologues
WO2001061344A1 (en) * 2000-02-17 2001-08-23 California Institute Of Technology Computationally targeted evolutionary design

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GIBRAT JEAN-FRANCOIS ET AL: "Surprising similarities in structure comparison", CURRENT OPINION IN STRUCTURAL BIOLOGY, vol. 6, no. 3, 1996, pages 377 - 385, XP002267031, ISSN: 0959-440X *
HOLM L ET AL: "MAPPING THE PROTEIN UNIVERSE", SCIENCE, vol. 273, 2 August 1996 (1996-08-02), pages 595 - 602, XP002916511, ISSN: 0036-8075 *
PIEHLER JACOB ET AL: "New structural and functional aspects of the type I interferon-receptor interaction revealed by comprehensive mutational analysis of the binding interface", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 51, 22 December 2000 (2000-12-22), pages 40425 - 40433, XP002267030, ISSN: 0021-9258 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11746137B2 (en) 2020-03-31 2023-09-05 Hanmi Pharm. Co., Ltd. Immunostimulating IL-2 analogs
US12415842B2 (en) 2020-03-31 2025-09-16 Hanmi Pharm. Co., Ltd. Immunostimulating IL-2 analogs

Also Published As

Publication number Publication date
US20080075672A1 (en) 2008-03-27
AU2003263552A8 (en) 2004-03-29
US20090131318A1 (en) 2009-05-21
US20040132977A1 (en) 2004-07-08
WO2004022593A8 (en) 2007-05-18
US20110142801A1 (en) 2011-06-16
US20080159977A1 (en) 2008-07-03
US8105573B2 (en) 2012-01-31
WO2004022593A2 (en) 2004-03-18
AU2003263552A1 (en) 2004-03-29
US7998469B2 (en) 2011-08-16
US20070224665A1 (en) 2007-09-27
CA2498319A1 (en) 2004-03-18
US8057787B2 (en) 2011-11-15
US20080274081A9 (en) 2008-11-06
US7650243B2 (en) 2010-01-19
US20070172459A1 (en) 2007-07-26
DE60332358D1 (en) 2010-06-10
US20080194477A1 (en) 2008-08-14
EP1539960B1 (en) 2010-04-28
US20070254838A1 (en) 2007-11-01
US20060020116A1 (en) 2006-01-26
US8114839B2 (en) 2012-02-14
ES2343518T3 (en) 2010-08-03
ATE466085T1 (en) 2010-05-15
US8052964B2 (en) 2011-11-08
US20090053147A1 (en) 2009-02-26
US20090123974A1 (en) 2009-05-14
US7611700B2 (en) 2009-11-03
EP1539960A2 (en) 2005-06-15

Similar Documents

Publication Publication Date Title
WO2004022593A3 (en) Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
EP1624065A3 (en) Agarase and gene thereof
AU2003252111A1 (en) Fluorescent proteins, nucleic acids encoding them and methods for making and using them
AU2002258630A1 (en) Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
AU2002256019A1 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
AU2002303137A1 (en) Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
AU2002257075A1 (en) Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
WO2003016465A3 (en) Cell cycle regulator protein
AU2003284579A1 (en) PROTEIN FORMING COMPLEX WITH c-Fos PROTEIN, NUCLEIC ACID ENCODING THE SAME AND METHOD OF USING THE SAME
AU2002258618A1 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
AU2003215179A1 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and used thereof
AU2003222241A1 (en) Isolated human enzyme proteins, nucleic acid molecules encoding human enzyme proteins, and uses thereof
AU2003209105A1 (en) Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
AU2002314731A1 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
AU2002311750A1 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
AU2002258629A1 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
AU2002303180A1 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
AU2002305909A1 (en) Isolated human transporter protein, nucleic acid molecules encoding human transporter protein, and uses thereof
AU2003225666A1 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
WO2003076644A9 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
AU2003215212A1 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
AU2003225626A1 (en) Isolated human enzyme proteins, nucleic acid molecules encoding human enzyme proteins, and uses thereof
AU2003221757A1 (en) Nucleic acid molecules encoding human proteins, and uses thereof
WO2005111069A3 (en) Morphogenic proteins and stimulatory factors in gene therapy
AU2003243913A1 (en) Protein or peptide (mimpd), nucleic acid that codes therefor, and uses of these substances

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2498319

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003794017

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003794017

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP